Skip to Content

Are you based in North America? If yes, switch to our North American website →

FIP1L1/CHIC2/PDGFRA Deletion/Fusion

Applications
haematology
Catalogue Numbers
LPH 032 (10 tests)
LPH 032-S (5 tests)

Deletion of CHIC2 in patients with idiopathic hypereosinophilic syndrome (HES) and chronic eosinophilic leukaemia (CEL) results in the fusion of FIP1L1 (FIP1-like 1) with PDGFRA (platelet derived growth factor receptor alpha) producing a tyrosine kinase which transforms haematopoietic cells.

In such patients, this activity is inhibited by imatinib mesylate (Gleevec), which is a tyrosine kinase inhibitor.

The diagnosis of the fusion gene can therefore lead to therapeutic choices for the patient1,2.

References

1. Cools J et al., N Eng J Med 2003;348:1201-14

2. Griffin JH et al., PNAS 2003;100:7830-5

Microscope Images

FIP1L1 CHIC2 PDGFRA Deletion Fusion magnified
Area of Interest*
MPN

Disclaimer

This product is intended to be used on Carnoy’s solution (3:1 methanol/acetic acid) fixed haematological samples.

*Disease information supported by the literature and is not a reflection of the intended purpose of this product.